EUROPEAN COMMISSION APPROVES ZINFORO TM (CEFTAROLINE FOSAMIL) FOR ADULT PATIENTS WITH SERIOUS SKIN INFECTIONS OR COMMUNITY ACQUIRED PNEUMONIA
28 August 2012 AstraZeneca today announced that the European Commission has granted Marketing Authorisation to ZINFORO TM (ceftaroline fosamil), a new intravenous cephalosporin antibiotic, for the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). This makes ZINFORO TM the only approved cephalosporin monotherapy in Europe with demonstrated clinical efficacy against methicillin-resistant Staphylococcus aureus (MRSA), a common cause of serious and difficult to treat complicated skin infections*. ZINFORO TM was